Clinical trials: Plaque Psoriasis Subjects
Psoriasis
Trial of HSK44459 Cream for the Management Plaque Psoriasis
Phase I Study Objectives: Primary: Assess the safety and tolerability of HSK44459 cream in 10 healthy adult participants and 10 patients with plaque psoriasis.
- Trial name
- NCT07623486
- Testing
- HSK44459 Cream, Vehicle
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Plaque Psoriasis
An Open-Label Study to Assess Safety
An Open-Label study to assess safety
- Trial name
- NCT03645499
- Testing
- Topical TA-102 A, Topical TA-102 B, Topical TA-102 C
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis
Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS
The primary objective of this study is to demonstrate equivalence of the pharmacokinetic (PK) profile of MSB11022 administered by either an auto-injector (AI) or a pre-filled syringe (PFS) as single subcutaneous (s.c.) injection…
- Conditions
- Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis
- Trial name
- NCT04018599
- Testing
- 40 mg MSB11022
- Where
- 2 sites in United States
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- Fresenius Kabi SwissBioSim GmbH
Plaque Psoriasis Vulgaris
Study to Assess the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of AZD0284 in Healthy Subjects
Plaque psoriasis vulgaris is a chronic inflammatory skin disorder, affecting 1-3% of the population in Europe and the United States of America (USA) and represents one of the most prevalent immune inflammatory diseases.
- Trial name
- NCT02976831
- Testing
- AZD0284
- Where
- United Kingdom
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Plaque Psoriasis
Autologous Natural Killer Cells in Subjects With Plaque Psoriasis
This is a non-randomized, dose escalating and open-labeled clinical trial to evaluate the safety of autologous natural killer cell (NK) infusions (IV) of "SNK01" in adults with plaque psoriasis.
- Trial name
- NCT03894579
- Testing
- Study Product: SNK01
- Where
- Mexico
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- NKGen Biotech, Inc.
Plaque Psoriasis
A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food Effect Investigation
The main purpose of the study is to determine if PF-06700841 is safe and well tolerated when administered to humans. A secondary purpose is to assess what the body does to PF-06700841 and to assess what PF-06700841 does to the…
- Trial name
- NCT02310750
- Testing
- PF-06700841 oral solution/suspension, PF-06700841 tablet
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Pfizer
Plaque Psoriasis
A Multicenter Study of 074-6751 Lotion in Subjects With Moderate Plaque Psoriasis
The primary objective of this study is to determine the efficacy and safety of 074-6751 Lotion applied twice daily for four weeks (28 days) in clinical subjects with moderate plaque psoriasis.
- Trial name
- NCT03167515
- Testing
- 074-6751 Lotion
- Where
- 5 sites in United States
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Ferndale Laboratories, Inc.
Moderate to Severe Plaque Psoriasis
Randomized, Double Blinded, Placebo Controlled, Single Dose Escalation Study of 608 in Healthy Subjects
This is a first-in-human, phase 1, single-center, randomized, double blinded, placebo-controlled, single dose-escalation study to evaluate the safety, tolerability, PK, of 608 following subcutaneous injection in healthy subjects.
- Trial name
- NCT04367441
- Testing
- 608
- Where
- China
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Plaque Psoriasis Vulgaris
Bioavailability of AZD0284 and IV Microtracer Study
The Sponsor is developing the study drug, AZD0284, for the potential treatment of Plaque psoriasis. Psoriasis is a skin condition that causes red, flaky, crusty patches of skin covered with silvery scales.
- Trial name
- NCT03029741
- Testing
- AZD0284, [14C]AZD0284
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Pharmacokinetics, Safety Issues
A Clinical Study With Adalimumab Biosimilar
The study aims to evaluate the pharmacokinetic profile, safety profile, and immunogenic potential of adalimumab of a new citrate-free formulation of adalimumab (Adalimumab Richmond) [Test Product] vs.
- Trial name
- NCT06291948
- Testing
- Humira® (adalimumab) AC Pen [Reference Product], Adalimumab Richmond [Test Product]
- Where
- Argentina
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Laboratorios Richmond S.A.C.I.F.
Healthy, Plaque Psoriasis
A Study to Investigate the Safety and Tolerability of CAN10 Antibody in Healthy Subjects and in Subjects With Plaque Psoriasis.
This is a first-in-human, randomized, double- blind, placebo-controlled, dose escalation study to investigate how different doses of CAN10 are tolerated, taken up by the body and how long CAN10 stays in the body.
- Trial name
- NCT06143371
- Testing
- CAN10
- Where
- Germany
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Plaque Psoriasis
Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris
This is an open label, investigator-blinded, cross over, prospective, single center study of subjects with plaque psoriasis. Taclonex® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Ointment and Taclonex Scalp®…
- Trial name
- PSTaclonex (NCT01707043)
- Testing
- Taclonex
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Wake Forest University
Psoriasis
Study Evaluating the Safety and Efficacy of Etanercept 50 mg Once Weekly in Subjects With Psoriasis
The primary objective is to assess the efficacy and safety of etanercept 50 mg administered once weekly in subjects with psoriasis over 12 weeks.
- Trial name
- NCT00333034
- Testing
- Etanercept
- Where
- 23 sites in Austria, Belgium and 8 more
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Psoriasis
Safety and Efficacy of IDP-122 Lotion When Applied Topically to Subjects With Moderate to Severe Plaque Psoriasis
A Phase 2, Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study.
- Trial name
- NCT02785185
- Testing
- IDP-122 Vehicle Lotion, IDP-122 Vehicle Cream, IDP-122 Lotion
- Where
- 13 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Acne, Atopic Dermatitis
Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers
The purpose of the study is to collect different samples for molecular characterization of inflammatory skin diseases.
- Conditions
- Acne, Atopic Dermatitis, Chronic Hand Eczema, Hidradenitis Suppurativa
- Trial name
- NCT05994976
- Testing
- Blood samples collection, Oral samples collection, Hair samples collection
- Where
- Canada
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Innovaderm Research Inc.
Psoriasis
Study to Evaluate Broadlumab vs Placebo and Ustekinumab
The purpose of the study is to evaluate the efficacy and safety of Induction and Maintenance Regimens of Brodalumab compared with Placebo and Ustekinumab in subjects with moderate to severe plaque psoriasis.
- Trial name
- AMAGINE-3 (NCT02786732)
- Testing
- 210mg Brodalumab, 140mg Brodalumab, Ustekinumab
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- MedDerm Associates
Moderate to Severe Plaque Psoriasis
A Phase I Clinical Trial of Single Subcutaneous Injection or Intravenous Infusion of SHR-1139 Injection in Healthy Chinese Subjects and Multiple Subcutaneous Injections in Patients With Moderate-to-severe Plaque Psoriasis
This is a clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamic and immunogenicity of SHR-1139 injection in healthy subjects who receive a single subcutaneous injection or intravenous infusion of…
- Trial name
- NCT07051538
- Testing
- SHR-1139 Injections
- Where
- China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Moderate to Severe Chronic Plaque Psoriasis
This is Comparative Study in Normal Healthy Subjects to Evaluate Pharmacokinetics, Safety, Tolerability of Bmab 1200 -Autoinjector (AI) After Single Subcutaneous Injection (45 mg) in Comparison With Bmab 1200 -Prefilled Syringe (PFS).
This is an open-label, 2-arm parallel-group study in normal healthy subjects to evaluate pharmacokinetics, safety, tolerability of Bmab 1200 -autoinjector (AI) after single subcutaneous injection (45 mg) in comparison with Bmab…
- Trial name
- NCT06738277
- Testing
- Bmab 1200 (Biosimilar Ustekinumab)
- Where
- India
- Volunteers
- 186 people, healthy volunteers welcome
- Sponsor
- Biocon Biologics UK Ltd
Plaque Psoriasis
Safety, Tolerability and Pharmacokinetics of MK-0873 Following Patch Application in Healthy Participants and Psoriasis Participants (MK-0873-020)
This study will evaluate the incidence of erythema and other local cutaneous irritation after administration of MK-0873 by patch or cream formulation in healthy participants and participants with mild psoriasis.
- Trial name
- NCT01140061
- Testing
- MK-0873 Patch, MK-0873 Cream, Plain patch
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Plaque Psoriasis
A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis
This first in human study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-06826647 in healthy subjects and subjects with plaque psoriasis.
- Trial name
- NCT03210961
- Testing
- PF-06826647 tablet, PF-06826647 oral suspension
- Where
- United States
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Pfizer